Blog
RSS FeedPosted by Michael Wonder on 22 Sep 2023
PMPRB report shows increased plan costs, promising pharmaceutical innovation: expert
20 September 2023 - A recent report by the Patented Medicine Prices Review Board shows increased growth for private drug ...
Posted by Michael Wonder on 13 Sep 2023
Paladin Labs announced favourable CADTH recommendation for Xcopri (cenobamate tablets)
12 September 2023 - Paladin Labs announced today that CADTH has recommended that Xcopri (cenobamate) be publicly reimbursed as adjunctive therapy ...
Posted by Michael Wonder on 30 Aug 2023
Mitsubishi Tanabe Pharma Canada announces that company's oral treatment formulation for amyotrophic lateral sclerosis has been added to the provincial drug plans in New Brunswick and Nova Scotia
29 August 2023 - Mitsubishi Tanabe Pharma Canada today announced that Radicava oral suspension (edaravone) is now covered under the New ...
Posted by Michael Wonder on 28 Aug 2023
CADTH to establish industry task force on real world data for post market drug evaluations
18 August 2023 - CADTH is establishing an industry task force that will build upon the recently released guidance for reporting ...
Posted by Michael Wonder on 24 Aug 2023
PMPRB report reveals most new medicines come to market with high treatment costs
22 August 2023 - The Patented Medicine Prices Review Board published today the 7th edition of its annual Meds Entry Watch ...
Posted by Michael Wonder on 07 Aug 2023
Alberta will cover pricey drug believed to extend and enhance lives of ALS patients
7 August 2023 - People diagnosed with ALS are usually given two to five years to live. ...
Posted by Michael Wonder on 27 Jul 2023
New Brunswick to publicly reimburse Albrioza for the treatment of ALS
24 July 2023 - New Brunswick lists Albrioza on its drug benefit formulary, becoming the fourth province to provide public ...
Posted by Michael Wonder on 27 Jul 2023
British Columbia to publicly reimburse Albrioza for the treatment of ALS
19 July 2023 - Amylyx Pharmaceuticals Canada announced today that the Company has entered into a Product Listing Agreement with British ...
Posted by Michael Wonder on 25 Jul 2023
Gilead Sciences announces its largest commitment to health equity for Australian and Canadian indigenous communities
23 July 2023 - $6 million USD in funding will help address health disparities among indigenous communities with a focus ...
Posted by Michael Wonder on 20 Jul 2023
Changes to CADTH’s rapid response service
20 July 2023 - As CADTH continues along the path of strategic transformation, we’re working hard to align the evidence products ...
Posted by Michael Wonder on 13 Jul 2023
Slynd (drospirenone) is now covered by the Régie de l’assurance maladie du Québec
12 July 2023 - Duchesnay is pleased to announce that Slynd (drospirenone 4 mg), used to prevent pregnancy in girls ...
Posted by Michael Wonder on 12 Jul 2023
Ruzurgi is now available and covered by the vast majority of public health and private insurance plans
11 July 2023 - Médunik Canada is pleased to announce that Ruzurgi (amifampridine) is now covered by the vast majority of ...
Posted by Michael Wonder on 29 Jun 2023
Ontario to publicly reimburse Albrioza for the treatment of ALS
28 June 2023 - Ontario lists Albrioza on its drug benefit formulary, becoming the first province to publicly reimburse Albrioza, ...
Posted by Michael Wonder on 15 Jun 2023
Amylyx Pharmaceuticals completes negotiation process and signs letter of intent with the pCPA for Albrioza for the treatment of ALS
15 June 2023 - Amylyx will now work with federal, provincial, and territorial drug plans to ensure public coverage is available ...
Posted by Michael Wonder on 13 Jun 2023
Pilot expert committee to support decision-making across the drug life cycle
8 June 2023 - CADTH, Canada’s drug and health technology agency, announces the creation and inaugural membership of a new ...